NBTX

Nanobiotix ADR

Oct 13 • 04:00PM ET

30.31

+6.71 28.43 %

Healthcare • Biotechnology • France • NASD

Peers: SRPT CRSP BMRN BEAM IONS NTLA FATE EDIT IMTX SGMO

Index	-	P/E	-	EPS (ttm)	-	Insider Own	21.05%	Shs Outstand	48.21M	Perf Week	33.06%
Market Cap	1.45B	Forward P/E	52.70	EPS next Y	0.58	Insider Trans	0.00%	Shs Float	37.83M	Perf Month	212.52%
Enterprise Value	1.48B	PEG	-	EPS next Q	-	Inst Own	0.04%	Short Float	0.20%	Perf Quarter	488.54%
Income	-	P/S	-	EPS this Y	62.11%	Inst Trans	3.23%	Short Ratio	1.28	Perf Half Y	903.64%
Sales	-	P/B	-	EPS next Y	194.81%	ROA	-	Short Interest	0.07M	Perf YTD	956.10%
Book/sh	-1.68	P/C	42.93	EPS next 5Y	-	ROE	-	52W High	30.23 0.26%	Perf Year	484.01%
Cash/sh	0.71	P/FCF	-	EPS past 3/5Y	0.85% 9.96%	ROIC	-	52W Low	2.76 998.19%	Perf 3Y	753.80%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.06% 10.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	54.68%	Oper. Margin	-	ATR (14)	2.80	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.63	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	71.58	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.63	EPS Q/Q	58.02%	SMA20	64.07%	Beta	0.62	Target Price	19.85
Payout	-	Debt/Eq	-	Sales Q/Q	-16.26%	SMA50	142.31%	Rel Volume	3.18	Prev Close	23.60
Employees	108	LT Debt/Eq	-	Earnings	Sep 30 AMC	SMA200	399.59%	Avg Volume	57.94K	Price	30.31
IPO	Dec 11, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	50.12% 30.65%	Trades		Volume	175,832	Change	28.43%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Guggenheim	Buy	$12
Dec-08-23	Initiated	Leerink Partners	Outperform	$11
Jan-06-21	Initiated	Evercore ISI	Outperform

Oct-07-25 08:00AM	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms (PR Newswire) -7.95%
Jul-07-25 04:15PM	NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) (GlobeNewswire) +13.37%
Jun-10-25 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
May-28-25 02:00AM	NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference (GlobeNewswire) +5.42%
May-21-25 04:15PM	Nanobiotix Provides First Quarter 2025 Operational and Financial Update (GlobeNewswire)
02:00AM	Loading…
May-14-25 02:00AM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
May-12-25 02:00AM	Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-05-25 02:00AM	Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer (GlobeNewswire) +5.96%
Apr-30-25 02:00AM	Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call (GlobeNewswire) +7.66%
Apr-14-25 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Apr-03-25 04:24PM	Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
Apr-02-25 04:15PM	NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results (GlobeNewswire) -5.03%
Mar-31-25 02:00AM	NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 (GlobeNewswire)
Mar-27-25 04:15PM	Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC (GlobeNewswire)
Mar-20-25 04:15PM	NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference (GlobeNewswire)
04:15PM	Loading…
Mar-17-25 04:15PM	NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 (GlobeNewswire) +18.51%
Mar-13-25 05:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) -6.97% +5.70%
Feb-12-25 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Jan-29-25 04:15PM	Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 (GlobeNewswire)
Jan-21-25 02:30AM	NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer (GlobeNewswire) +7.26%
Jan-09-25 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Dec-17-24 04:15PM	NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 (GlobeNewswire)
Dec-11-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Dec-09-24 04:15PM	NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer (GlobeNewswire) +9.67%
Nov-13-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Nov-12-24 02:30AM	NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms (GlobeNewswire)
Oct-31-24 03:30AM	NANOBIOTIX to Participate in Multiple Investor Conferences in November (GlobeNewswire)
Oct-11-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Sep-18-24 04:15PM	NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results (GlobeNewswire) +7.91%
Sep-04-24 04:15PM	NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth (GlobeNewswire)
04:15PM	Loading…
Sep-03-24 04:15PM	Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -12.17%
Aug-08-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Jul-09-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Jun-12-24 04:15PM	NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 (GlobeNewswire) -8.12%
Jun-11-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Jun-02-24 10:00AM	Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Na ve or Resistant to Prior anti-PD-1 Therapy (GlobeNewswire)
May-28-24 04:15PM	NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call (GlobeNewswire)
May-23-24 04:15PM	NANOBIOTIX to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +6.27%
May-22-24 02:00AM	NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update (GlobeNewswire) -12.52%
May-21-24 04:15PM	Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth (GlobeNewswire)
May-16-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
May-15-24 04:15PM	NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 (GlobeNewswire)
May-14-24 04:15PM	NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer (GlobeNewswire) +6.42%
Apr-24-24 04:40PM	NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Apr-17-24 04:15PM	NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 (GlobeNewswire)
Apr-13-24 10:02AM	11 Best Nanotechnology Stocks To Invest In (Insider Monkey)
Apr-10-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +6.49%
Apr-02-24 04:15PM	Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation (GlobeNewswire)
Mar-06-24 04:15PM	Nanobiotix to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-13-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) -6.16%
Jan-31-24 04:15PM	Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-30-24 11:02AM	Baillie Gifford Bolsters Stake in Nanobiotix SA (GuruFocus.com)
Jan-29-24 04:15PM	Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study (GlobeNewswire)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-11-24 04:32PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Dec-26-23 02:00AM	Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets (GlobeNewswire)
Dec-13-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Dec-04-23 04:22PM	Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation JJDC, Inc. (GlobeNewswire)
Nov-13-23 04:15PM	NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update (GlobeNewswire)
Nov-09-23 04:15PM	NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023 (GlobeNewswire)
Nov-08-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Nov-07-23 04:01PM	NANOBIOTIX Announces Closing of Global Offering (GlobeNewswire)
Nov-06-23 02:00AM	NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M (GlobeNewswire)
Nov-02-23 10:49AM	NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M (GlobeNewswire) -14.01%
Nov-01-23 06:32PM	NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant (GlobeNewswire) -8.00%
Oct-23-23 02:00AM	NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023 (GlobeNewswire)
Oct-11-23 04:27PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Oct-04-23 04:30PM	Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months (GlobeNewswire) -14.35%
Sep-29-23 04:15PM	NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology (GlobeNewswire) +5.04% +5.06%
Sep-28-23 04:15PM	NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer (GlobeNewswire)
Sep-26-23 04:15PM	NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023 (GlobeNewswire)
Sep-19-23 04:15PM	Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023 (GlobeNewswire) -10.85%
Sep-13-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +5.35%
Sep-05-23 04:15PM	NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer (GlobeNewswire)
Aug-31-23 04:15PM	NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 04:15PM	NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3 (GlobeNewswire) -6.08%
Aug-04-23 04:15PM	NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023 (GlobeNewswire) +8.89%
Jul-20-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +10.61% +17.52%
Jul-19-23 04:15PM	NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers (GlobeNewswire)
Jul-10-23 02:00AM	NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3 (GlobeNewswire) +24.52%
Jun-08-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
May-17-23 04:15PM	NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update (GlobeNewswire) -7.24%
May-05-23 01:30AM	NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company (GlobeNewswire) +229.05%
Apr-24-23 07:33PM	NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire) +14.43% -39.95%
Apr-17-23 04:15PM	NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023 (GlobeNewswire)
Apr-11-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) -5.31%
Mar-27-23 04:15PM	Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call (GlobeNewswire)
Mar-14-23 04:15PM	Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023 (GlobeNewswire) +8.88% -8.71%
Feb-14-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +5.99% -7.29%
Jan-11-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) -6.49% +12.47%
Dec-27-22 01:45AM	NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer (GlobeNewswire) -5.75%
Dec-21-22 04:15PM	NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement (GlobeNewswire)
Dec-08-22 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +5.76%
Nov-15-22 04:15PM	NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -8.88%
Nov-14-22 04:15PM	NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer (GlobeNewswire) +7.89%
Nov-10-22 08:28AM	Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients (Benzinga)
02:00AM	NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Nov-09-22 04:15PM	NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update (GlobeNewswire)
Nov-08-22 04:15PM	NANOBIOTIX Voting Rights and Shares Capital of the Company (GlobeNewswire) +7.89%
Nov-02-22 04:15PM	NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3 (GlobeNewswire)

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Levy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NBTX

Nanobiotix ADR

Upgrade your FINVIZ experience